scispace - formally typeset
A

Alan Ashworth

Researcher at University of California, San Francisco

Publications -  589
Citations -  82138

Alan Ashworth is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 134, co-authored 578 publications receiving 72089 citations. Previous affiliations of Alan Ashworth include Imperial College London & Papworth Hospital.

Papers
More filters
Journal ArticleDOI

Expression of Xist during mouse development suggests a role in the initiation of X chromosome inactivation

TL;DR: The data support a direct role for Xist in the initiation of X inactivation, and the earliest Xist expression in morulae and blastocysts is imprinted, resulting in specific expression of the paternal Xist allele.
Journal ArticleDOI

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

TL;DR: Although every SSP identifies molecular subtypes with similar survival, they do not reliably assign the same patients to the same molecular subtype, so stringent standardisation of methodologies and definitions for identification of breast cancer molecular sub types is needed.
Journal ArticleDOI

CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells

TL;DR: Differential staining of mammary epithelial cells for CD24 can be used to simultaneously isolate pure populations of non-epithelial, myoepithel/basal and luminal epithelialcells, which is key for understanding mammaries epithelial stem cells in normal tissue biology and carcinogenesis.
Journal ArticleDOI

MAP kinase phosphatases

TL;DR: An emerging family of structurally distinct dual-specificity serine, threonine and tyrosine phosphatases that act on MAP kinases consists of ten members in mammals, and members have been found in animals, plants and yeast.
Journal ArticleDOI

Translating cancer research into targeted therapeutics

TL;DR: The issues involved in cancer drug development are highlighted and ways in which this process can be improved and expedited are suggested.